Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

• Main Authors: Luigi Gargiulo (Author), Luciano Ibba (Author), Ruggero Cascio Ingurgio (Author), Piergiorgio Malagoli (Author), Fabrizio Amoruso (Author), Anna Balato (Author), Federico Bardazzi (Author), Pina Brianti (Author), Giovanna Brunasso (Author), Martina Burlando (Author), Anna E. Cagni (Author), Marzia Caproni (Author), Carlo G. Carrera (Author), Andrea Carugno (Author), Francesco Caudullo (Author), Aldo Cuccia (Author), Paolo Dapavo (Author), Eugenia V. Di Brizzi (Author), Valentina Dini (Author), Francesca M. Gaiani (Author), Paolo Gisondi (Author), Claudio Guarneri (Author), Claudia Lasagni (Author), Gaetano Licata (Author), Francesco Loconsole (Author), Angelo V. Marzano (Author), Matteo Megna (Author), Santo R. Mercuri (Author), Maria L. Musumeci (Author), Diego Orsini (Author), Simone Ribero (Author), Valentina Ruffo Di Calabria (Author), Francesca Satolli (Author), Davide Strippoli (Author), Massimo Travaglini (Author), Emanuele Trovato (Author), Marina Venturini (Author), Leonardo Zichichi (Author), Mario Valenti (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractPurpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in pati...